Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Heroin overdose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4 result(s) found for: Heroin overdose. Displaying page 1 of 1.
    EudraCT Number: 2016-001877-34 Sponsor Protocol Number: HOT-Treated Start Date*: 2016-11-25
    Sponsor Name:South London and Maudsley NHS Foundation Trust [...]
    1. South London and Maudsley NHS Foundation Trust
    2. King's College London
    Full Title: Improving understanding of Heroin Overdose Testing: diamorphine dose-escalation testing in a treated population
    Medical condition: Opioid Overdose
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022117 - Injury, poisoning and procedural complications 10033295 Overdose PT
    20.0 10022117 - Injury, poisoning and procedural complications 10033299 Overdose effect LLT
    20.1 10022117 - Injury, poisoning and procedural complications 10067695 Acute overdose LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-001384-30 Sponsor Protocol Number: 05/010/SAN Start Date*: 2006-08-01
    Sponsor Name:Brighton and Sussex Universities Hospitals Trust Research and Development Directorate
    Full Title: Standard vs reduced dose naloxone for the reversal of opiate overdose. Does dose modification increase the likelihood of reaching hospital and entering a substance misuse programme?
    Medical condition: Accidental, recreational heroin (and other opiate) overdose.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004072-22 Sponsor Protocol Number: NINA-1 Start Date*: 2017-12-07
    Sponsor Name:Norwegian University of Science and Technology (NTNU)
    Full Title: NTNU Intranasal Naloxone Trial Double blinded, double dummy, randomised controlled trial of intranasal naloxone for pre hospital use
    Medical condition: We investigate the reversal of opioid overdoses in the pre hospital setting
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10022117 Injury, poisoning and procedural complications SOC
    20.0 10022117 - Injury, poisoning and procedural complications 10071947 Exposures, chemical injuries and poisoning HLGT
    20.0 10022117 - Injury, poisoning and procedural complications 10035777 Poisoning and toxicity HLT
    21.1 10022117 - Injury, poisoning and procedural complications 10070863 Toxicity to various agents PT
    20.1 10022117 - Injury, poisoning and procedural complications 10072946 Opioid toxicity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2022-001997-70 Sponsor Protocol Number: EXCELLENCE/0421/0543v1 Start Date*: 2022-11-16
    Sponsor Name:University of Cyprus
    Full Title: Efficacy of Ketamine for the Prevention of Relapse in Patients with Opioid-Use Disorders (OUD)
    Medical condition: Methadone and buprenorphine comprise a first-line, evidence-based opioid substitution treatment (OST) for OUD patients. Unfortunately, retention and adherence to OST treatment is currently a major ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10037175 - Psychiatric disorders 10019935 Heroin addiction LLT
    20.1 10037175 - Psychiatric disorders 10030900 Opium addiction LLT
    20.0 10037175 - Psychiatric disorders 10012378 Depression PT
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CY (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 03:29:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA